We thank the reviewer for their suggestion and have now computed AMPA-NMDA ratios and included a phrase in lines 424-425 that summarises the statistics for the comparison of AMPA-NMDA ratios between the GluN2B variants (WT and mutants).
3) A scheme summarizing how different molecular defects can converge on similar NMDAR-mediated EPSCs would be helpful in the discussion 4) A small commentary on the possible functional significance of the identified mutation properties for the pathogenesis of certain diseases would be interesting.